Magdalena aiming to submit Investigational New Drug application in 2024 to the FDA for this next-generation psychoactive prescription drug candidate…
NORTHAMPTON, MA / ACCESSWIRE / January 30, 2024 / Gilead Sciences - The personal journeys of six people in the…
– No differentiation syndrome events reported – – 100% CR rate with 7+3 in newly diagnosed NPM1-m and KMT2A-r AML…
MILAN, Italy, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Olon Group announces the construction of a cutting-edge High Potency API suite.…
Press Release High-Performance Computing, simulations and AI: Qubit Pharmaceuticals, Institut Curie and the University of Bordeaux team…
Gdańsk, Poland – 30 January 2024 – PolTREG S.A. (Warsaw Stock Exchange: PTG) , a clinical-stage biotechnology company developing…
PRESS RELEASE – INSIDE INFORMATION BioSenic patent granted in Canada for broader protection of its ATO therapeutic platform Composition-of-matter…
— First medicine approved under new “1+” mechanism by HKSAR Government, providing an important treatment option to patients in Hong…
VANCOUVER, BC / ACCESSWIRE / January 30, 2024 / MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), (the "Company" or "MindBio"), announces it is…
HOUSTON, TX / ACCESSWIRE / January 29, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company…